← Silence Therapeutics plc (SLN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Silence Therapeutics plc (SLN)
Pharmaceutical Preparations · market cap $717M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Silence Therapeutics plc (SLN) is a UK-based RNAi therapeutics company with ~116 employees and a market cap of ~$1.49B. Its lead asset SLN124 is in Phase 2 for Polycythemia Vera, with SLN360 in Phase 2 for cardiovascular disease and Atu027/gemcitabine in Phase 2 for pancreatic ductal carcinoma. The company faces a critical near-term liquidity crisis with only ~$5.7M cash and approximately 1.1 months of runway.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SLN124 | Phase 2 | Polycythemia Vera |
| SLN360 | Phase 2 | Cardiovascular Diseases |
| Atu027 & gemcitabine in lead in safety period | Phase 2 | Carcinoma, Pancreatic Ductal |
Price & technical context
3-month
+0.3%
6-month
+78.6%
12-month
+108.0%
52-wk range
$4.30–$15.43
vs 50-day MA
-16.3%
vs 200-day MA
+29.3%
Realized vol
81.2%
Max drawdown
-88.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SLN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.